




Novel Insights into *Staphylococcus aureus* Deep Bone Infections: the Involvement of Osteocytes

Dongqing Yang,^a Asiri R. Wijenayaka,^a Lucian B. Solomon,^a Stephen M. Pederson,^b David M. Findlay,^a  Stephen P. Kidd,^{c,d} Gerald J. Atkins^a

^aCentre for Orthopaedic & Trauma Research, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia

^bBioinformatics Hub, School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia

^cAustralian Centre for Antimicrobial Resistance Ecology, University of Adelaide, Adelaide, South Australia, Australia

^dResearch Centre for Infectious Disease, School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia

ABSTRACT Periprosthetic joint infection (PJI) is a potentially devastating complication of orthopedic joint replacement surgery. PJI with associated osteomyelitis is particularly problematic and difficult to cure. Whether viable osteocytes, the predominant cell type in mineralized bone tissue, have a role in these infections is not clear, although their involvement might contribute to the difficulty in detecting and clearing PJI. Here, using *Staphylococcus aureus*, the most common pathogen in PJI, we demonstrate intracellular infection of human-osteocyte-like cells *in vitro* and *S. aureus* adaptation by forming quasi-dormant small-colony variants (SCVs). Consistent patterns of host gene expression were observed between *in vitro*-infected osteocyte-like cultures, an *ex vivo* human bone infection model, and bone samples obtained from PJI patients. Finally, we confirm *S. aureus* infection of osteocytes in clinical cases of PJI. Our findings are consistent with osteocyte infection being a feature of human PJI and suggest that this cell type may provide a reservoir for silent or persistent infection. We suggest that elucidating the molecular/cellular mechanism(s) of osteocyte-bacterium interactions will contribute to better understanding of PJI and osteomyelitis, improved pathogen detection, and treatment.

IMPORTANCE Periprosthetic joint infections (PJIs) are increasing and are recognized as one of the most common modes of failure of joint replacements. Osteomyelitis arising from PJI is challenging to treat and difficult to cure and increases patient mortality 5-fold. *Staphylococcus aureus* is the most common pathogen causing PJI. PJI can have subtle symptoms and lie dormant or go undiagnosed for many years, suggesting persistent bacterial infection. Osteocytes, the major bone cell type, reside in bony caves and tunnels, the lacuno-canalicular system. We report here that *S. aureus* can infect and reside in human osteocytes without causing cell death both experimentally and in bone samples from patients with PJI. We demonstrate that osteocytes respond to infection by the differential regulation of a large number of genes. *S. aureus* adapts during intracellular infection of osteocytes by adopting the quasi-dormant small-colony variant (SCV) lifestyle, which might contribute to persistent or silent infection. Our findings shed new light on the etiology of PJI and osteomyelitis in general.

KEYWORDS *Staphylococcus aureus*, bone infection, osteomyelitis, periprosthetic joint infection, small-colony variant, stress adaptation

Received 20 February 2018 **Accepted** 29 March 2018 **Published** 24 April 2018

Citation Yang D, Wijenayaka AR, Solomon LB, Pederson SM, Findlay DM, Kidd SP, Atkins GJ. 2018. Novel insights into *Staphylococcus aureus* deep bone infections: the involvement of osteocytes. mBio 9:e00415-18. <https://doi.org/10.1128/mBio.00415-18>.

Invited Editor Mark S. Smeltzer, University of Arkansas for Medical Sciences

Editor Richard P. Novick, Skirball Institute of Biomolecular Medicine, New York University Medical Center


Copyright © 2018 Yang et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Gerald J. Atkins, gerald.atkins@adelaide.edu.au.

D.Y. and A.R.W. contributed equally to this work.

Joint arthroplasty is a common and highly successful procedure; however, more than 1% of primary hip (1) and 1 to 3% of primary knee (2) arthroplasties fail due to periprosthetic joint infection (PJI). PJI carries a high risk of in-hospital and 5-year mortality (3, 4), and the cure rate after 2 years has been reported to be as low as 67% (5). These poor outcomes are due in part to incomplete knowledge of PJI disease etiology (6). In bone, osteoblasts (7) and osteoclasts (8) have been investigated in relation to bacterial infection. However, insufficient attention has been given to the role of the osteocyte in bone infection, despite this cell type constituting approximately 90 to 95% of cells in bone (9, 10). It has been reported that bacteria can reside in osteocytes *in vivo* (11, 12), and a recent study (13) demonstrated the ability of *Staphylococcus aureus* to invade the lacuno-canalicular spaces of cortical bone in an experimental osteomyelitis model, although infection of osteocytes *per se* was not reported in that study. The result of direct interaction between human osteocytes and bacteria remains to be investigated.

Staphylococci, in particular *S. aureus* and the coagulase-negative species *Staphylococcus epidermidis*, have been identified as the most common causative pathogens in bone infection (14, 15). In this study, *S. aureus* was investigated because of its common association with bone infection and its well-characterized ability to exist in the quasi-dormant small-colony variant (SCV) lifestyle, which potentially contributes to a chronic disease state (16). The interaction between human osteocytes and *S. aureus* was investigated first by experimental infection using the WCH-SK2 strain (17), a methicillin-resistant *S. aureus* (MRSA) strain, at defined multiplicities of infection (MOIs). We utilized our well-characterized model of human-osteocyte-like cells generated by differentiation of human primary osteoblastic cultures to a mature, osteocyte-like state (18, 19). Day 28 differentiated osteocyte-like cells (Fig. S1) were cocultured with WCH-SK2 for 2 h, after which time extracellular bacteria were lysed using lysostaphin and washed to remove debris, leaving only internalized bacteria. There was no effect of infection on osteocyte-like cell viability, evidenced by the similar total cell numbers between the control and infected groups 30 days postinfection (Fig. 1A). Using live-cell imaging, uninfected osteocyte-like cells were observed to be relatively quiescent (see Movie S1 in the supplemental material), whereas cells exposed to green fluorescent protein (GFP)-expressing *S. aureus* (strain RN6390 [20]) were measurably active, with cell membranes and dendritic processes moving on average 25 μm nondirectionally in a 19-h time frame (Movie S2; Fig. 1B). Osteocyte-like cells were observed to have internalized WCH-SK2 cells; by 24 h postinfection, both dying bacteria with compromised cell walls (Fig. 1C) and actively proliferating *S. aureus* cells were observed in host cells (Fig. 1D to F). Among the proliferating *S. aureus* cells, distinctive phenotypes of dividing bacteria, including those with symmetrical and completely separated cell walls (Fig. 1D) and those with asymmetrical and incompletely separated cell walls (Fig. 1E and F), were observed. *S. aureus* cells with uneven and/or incomplete division were previously characterized as an adaptation to stress and, possibly, the initiation of SCV development. SCVs have a lower growth rate and lower virulence than normal cells but are able to persist inside host cells (16), avoiding immune and therapeutic antimicrobial interventions. Indeed, distinct bacterial colony types were grown from osteocyte-like lysates of cells of large (>1-mm) or small (<0.2-mm) sizes, the latter appearing as unpigmented (Fig. 1G). Overall, the total number of recovered CFU decreased from $\sim 10^5$ per well at day 1 to $\sim 1,500$ per well at day 5 (Fig. 1H). At day 5, approximately 80% of the total recovered colonies were of the small, unpigmented phenotype (Fig. 1G and H). A comparison of the gene expression profiles of the small and large colonies (in pools of 10 colonies of each type) showed that the metabolism-related genes accessory gene regulator A (*agrA*), staphylococcal accessory regulator A (*sarA*), and alkaline shock protein 23 (*asp23*) and the bacterial-virulence-related genes alpha-hemolysin (*hla*) and delta-hemolysin (*hld*) were not different between colony types, whereas the stress adaptation-related gene sigma factor B (*sigB*) was found to be increased 50-fold in small colonies (Fig. 1I). These data are consistent with those of previous studies showing that the formation of SCV cell types is strongly associated with *sigB* expression



(Continued on next page)

level (21, 22). Our finding suggests that the development of SCVs was initiated following internalization by human-osteocyte-like cells. In response to *S. aureus* invasion, the expression of a number of chemokine genes, including the neutrophil chemoattractants *CCL5*, *CXCL1*, and *CXCL8* and chemokines related to T cell activation, *CXCL9*, *CXCL10*, and *CXCL11*, was strongly upregulated. The elevation of these chemokines was dependent on exposure to live *S. aureus* and did not occur in the presence of heat-killed cells (Fig. 1J). The protein production of *CCL5* (regulated upon activation, normal T cell expressed and secreted [RANTES]) and *CXCL10* (interferon gamma-induced protein 10 [IP10]) but not *CXCL8* (interleukin-8 [IL-8]) were confirmed to be secreted by exposed osteocyte-like cells in an MOI-dependent manner (Fig. 1K). A comprehensive transcription profile of the osteocyte-like cell response to *S. aureus* WCH-SK2 exposure *in vitro* was determined by microarray and bioinformatics analyses. These revealed a large set of 1,526 differentially expressed genes (Fig. S2A). Network analysis revealed numerous gene ontology (GO) term “communities” relating to a variety of host innate immune responses and cell metabolic activities (Fig. S2B).

To investigate whether *S. aureus* is capable of penetrating human cancellous bone to contact osteocytes, fresh bone specimens were tested for susceptibility to bacterial infection *ex vivo*. Following a 12-h culture period, the presence of *S. aureus* in both occupied (Fig. 2A and B) and empty (Fig. 2C) osteocyte lacunae was observed by immunostaining. The specificity of antibody staining was validated by the use of a primary, isotype-matched control antibody (Fig. 2D). Consequently, the mRNA levels of *CXCL1*, *CLCX8*, *CXCL9*, *CXCL10*, and *CXCL11* were shown to be elevated following *S. aureus* invasion (Fig. 2E). The presence of intracellular *S. aureus* in osteocytes and the above-described host cell response were also confirmed in bone retrieved from PJI patients. Acetabular bone specimens from two patient cohorts, 24 with PJI (15 males and 9 females; age range, from 39 to 89 years) and 13 control patients with femoral neck fracture and no evidence of infection (3 males and 10 females; age range, from 22 to 87 years) were collected for examination. All members of the PJI cohort were *S. aureus* culture positive, as determined by routine diagnostic analysis of surgical biopsy specimens, and all were undergoing treatment by staged-revision total hip replacement surgery. A specimen from the iliac wing was also obtained from each patient to be able to compare the biopsy specimens with a skeletal site that was distal from the infected region and displayed no clinical signs of infection. All biopsy procedures were approved by the Human Research Ethics Committees of the Royal Adelaide Hospital and the University of Adelaide. Immunostaining (Fig. 2F), as well as intense staining of individual osteocyte lacunae and apparently viable osteocytes (Fig. 2F'), was carried out to examine specimens for the presence of *S. aureus* within bone tissue, and it identified *S. aureus* within the bone marrow. A three-dimensional reconstruction video of *in situ* confocal microscopy, scanning to a depth of 9 μm , was generated to confirm intracellular, cytoplasmic immunostaining of *S. aureus* (Movie S3). The specificity of staining was validated using isotype-matched antibody (Fig. 2G and G'). No positive staining was detected either in the corresponding iliac wing sample from the same patient or in acetabular samples from the femoral fracture cohort (Fig. S3A and S3B). Consistent with the presence of *S. aureus* in the PJI cohort bone, mRNA levels of a number of chemokines stimulated by infection, including *CCL5*, *CXCL9*, *CXCL10*, and *CXCL11* (Fig. 2H), were upregulated in bone specimens from the infected acetabulum site of PJI patients but not the uninfected iliac wing. Significantly elevated levels of these mRNA species were not observed in specimens from either acetabulum or iliac sites from the fracture cohort.

In summary, we have confirmed that *S. aureus* is capable of infecting human

FIG 1 Legend (Continued)

indicated. ND, nondetectable. (K) Production of the chemokines RANTES, IL-8, and IP10 by osteocyte-like cells after 24 h of exposure to *S. aureus* WCH-SK2 at MOIs of 0, 1, 10, and 100 (mean levels \pm SEM from 3 independent biological replicates); the effect of each MOI on chemokine production was tested by one-way ANOVA, with relevant *P* values indicated.




FIG 2 Interaction between osteocytes and *S. aureus* *ex vivo* and in clinical PJI specimens. (A and B) Presence of *S. aureus* (white arrowheads) in osteocyte (Ot)-occupied lacunae in bone tissue after *ex vivo* infection; (C) presence of *S. aureus* (white arrowhead) in empty lacunae (EL); (D) isotype-matched control immunostaining of infected bone tissue; (E) upregulation of mRNA levels of *CXCL1*, *CXCL8*, *CXCL9*, *CXCL10*, and *CXCL11* in infected bone samples in comparison to control samples (the y axis represents log₂ values of mRNA fold change [FC] and mean normalized expression \pm SEM from 3 independent biological replicates); (F) immunostaining targeting *S. aureus* (red fluorescence) in the acetabular bone of a PJI patient, with the box marked by a broken red line indicating the enlarged area in panel F'; (F') high-magnification image of *S. aureus* staining of osteocytes/osteocyte lacunae (white arrowheads); (G) isotype-matched control immunostaining of PJI patient acetabular bone; (G') high-magnification image of control staining of osteocytes/osteocyte lacunae; (H) boxplots (median with interquartile range) showing relative mRNA levels (normalized to that of the glyceraldehyde-3-phosphate dehydrogenase [GAPDH] gene) of *CCL5* ($P = 0.026$), *CXCL9* ($P = 0.038$), *CXCL10* ($P = 0.054$), and *CXCL11* ($P = 0.0070$) in bone specimens from the iliac wing and acetabulum of the PJI cohort ($n = 23$) and femoral fracture cohort ($n = 13$). P values indicate the comparisons between acetabulum bone and iliac wing bone from PJI patients. BM, bone marrow.

osteocytes both in *in vitro* cell cultures and in *ex vivo*-infected bone tissue. We also demonstrate the presence of *S. aureus* antigens in viable osteocytes present in regions of infected PJI patient bone. Our findings extend previous observations that undifferentiated osteoblasts can become infected by *S. aureus* (7) and that *S. aureus* can invade the lacuno-canalicular spaces of mouse cortical bone in an experimental infection model (13). Our *in vitro* and clinical findings demonstrate that osteocytes are capable of responding robustly to *S. aureus* invasion by producing immune mediators, consistent with previous findings with other nonprofessional antigen-presenting cell types, including osteoblasts (23). Some of the upregulated chemokines in this study, such as RANTES (24) and IP10 (25), were previously shown to have direct antimicrobial activity to clear extracellular bacteria. In our osteocyte-like cell model, whether the reduced live

intracellular *S. aureus* cell number is associated with chemokine production, production of another mediator, or lysosomal digestion by the host cell or a combination of all three is an important question that needs to be addressed. This might potentially give rise to a novel therapeutic approach, stimulating osteocytes to clear the viable intracellular bacteria that are refractory to the effects of antibiotics. The bony location of the infected osteocyte may render them refractory to clearance by immune cells, and, as such, osteocytes may be an immune-privileged cell type. The osteocyte may therefore serve as a reservoir of bacteria for future reinfection, perhaps explaining the high prevalence of infections that become apparent only after long periods of time or recur following surgical/medical management.

Our findings also demonstrate the capacity for planktonic-phase *S. aureus* to rapidly switch to an SCV lifestyle upon interaction with osteocytes, indicative of an adaptation to stress from the host cell. A previous study identified the presence of *S. aureus* SCVs in fibroblasts in tissue from chronic PJI patients and suggested that infections with SCVs represented a problematic subset of cases (26). Our findings suggest that SCVs form upon interaction with osteocytes, and, as such, all *S. aureus* PJIs have the potential to become chronic if this occurs. SCVs have been demonstrated to be significantly less sensitive to most antibiotic treatments, and this mechanism of dormancy has been suggested to be a strategy for bacteria to survive, either in biofilm or inside host cells in chronic diseases (27). Other cell types, such as fibroblasts (26) and osteoclasts (8), have been proposed as reservoirs for *S. aureus* infection in PJIs; however, these are relatively short-lived cells. Osteoblast infection has also been proposed, and while the nature of this cell type is transient, the cell type is capable of differentiating into osteocytes, and infected osteoblasts have been shown to retain the ability to differentiate *in vitro* (7). Given that differentiated osteocytes are the most numerous and long-lived cell type encountered by bacteria in hard-bone tissue and demonstrate viability upon infection with intracellular *S. aureus*, osteocytes might be the ideal host cell type for *S. aureus* to survive in the long term. We propose that further investigation of the role of the osteocyte in PJI is warranted.

Human-osteocyte-like cell model. Isolation and maintenance of primary human osteoblasts were performed as previously established (18). Cells were then differentiated in alpha minimal essential medium (α MEM; Life Technologies, Inc., Grand Island, NY, USA) containing 5%, vol/vol, fetal calf serum (FCS; Thermo-Fisher Scientific, Scoresby, VIC, Australia), 1.8 mM potassium dihydrogen phosphate (Sigma-Aldrich, St. Louis, MO, USA), 100 μ M ascorbate-2-phosphate (Sigma-Aldrich), and standard tissue culture L-glutamine–antibiotics (Life Technologies, Inc.). Cells were allowed to differentiate for 4 weeks in a humidified incubator in an atmosphere of 5% CO₂–normoxia at 37°C.

Bacterial strains. The clinical isolate of *S. aureus* used, unless otherwise stated, was WCH-SK2 (17). *S. aureus* strain RN6390 engineered with green fluorescent protein (GFP) (20) was kindly provided by Clare Cooksley (Basil Hetzel Institute, SA, Australia). All bacterial-suspension cultures were maintained in Terrific broth (ThermoFisher Scientific, Carlsbad, CA, USA) at 37°C with agitation, and bacterial colonies were grown on Terrific broth with 1.2%, wt/vol, agar.

Human bone biopsy specimens. Bone specimens from two cohorts, namely, patients identified with *S. aureus*-related PJI following total hip replacement or a femoral fracture, were collected for immunohistochemistry and gene expression analyses. Samples from two different skeletal sites, the acetabulum and iliac wing, were included. Bone samples from femoral fracture patients were also utilized for *ex vivo* infection experiments. All the usage and operation procedures for collecting human bone biopsy specimens were approved by the Human Research Ethics Committees of the Royal Adelaide Hospital and the University of Adelaide.

In vitro and ex vivo infection of osteocytes and bacterial colony recovery. *S. aureus* WCH-SK2 actively growing in its log-phase stage was used for *in vitro* and *ex vivo* infection experiments, except for the live-cell imaging observation. A colorimetric

method measuring light absorption of a bacterial suspension at 600 nm was employed to determine the number of CFU per volume for standardizing a multiplicity of infection (MOI). Bacterial suspensions were adjusted in phosphate-buffered saline (PBS) to achieve an MOI of 1, 10, or 100 for the purposes of testing the dosage-dependent effects of MOIs on the production of chemokine levels; otherwise, an MOI of 100 was used. Bacterial suspensions were then used to inoculate differentiated osteocyte-like cultures. After an initial infection period of 2 h, media were aspirated and replaced with antibiotic-free differentiation medium supplemented with 20 $\mu\text{g/ml}$ lysostaphin (Sigma-Aldrich) to lyse remaining extracellular bacteria. An estimation of total host cell number 30 days postinfection in both control and infected cultures was carried out by counting the eukaryotic nuclei number using DAPI (4',6-diamidino-2-phenylindole) staining and fluorescence microscopy (Olympus IX71 microscope) and by image analysis using ImageJ software (NIH, Bethesda, MD, USA). Osteocyte-like cultures were lysed in TRIzol reagent 24 h postinfection before performance of gene expression analyses as described below, and cell culture supernatants were collected for measuring secreted protein levels of RANTES (enzyme-linked immunosorbent assay [ELISA] kit; Caribbean Park, VIC, Australia), IL-8 (ELISA kit), and IP10 (DIP100; R&D Systems, Minneapolis, MN, USA) by ELISA. For *ex vivo* infection experiments, bone specimens from femoral fracture patients were dissected into 1-mm³ pieces and washed with PBS to remove the bone marrow fraction. Cleaned bone pieces were then cultured without bacteria as a control and with *S. aureus* adjusted to 10³ CFU per mm³ of bone volume as the infected group for 12 h. Specimens from both groups were then processed both for total RNA extraction using the TRIzol method and for immunostaining to detect *S. aureus*.

For the recovery of intracellular bacteria, osteocyte-like cultures were lysed in sterile water. Cell lysates were evenly distributed on Terrific broth/agar plates and cultured overnight at 37°C in 5% CO₂. Agar plates were then kept at room temperature under aerobic conditions for 48 h to develop a gold pigmentation in resultant colonies, which is a typical feature of planktonic *S. aureus*. Following such growth development, colonies with a 0.2-mm diameter or less were counted as SCVs; both total colony counts and percentages of cells that were SCVs were recorded from each of the retrieval time points.

Live-cell imaging of osteocyte-like cell infection. For live-cell imaging, primary human osteoblasts were seeded in 8-well chamber slides (ibidi GmbH, Martinsried, Germany) and differentiated for 4 weeks, as described above. GFP-expressing *S. aureus* RN6390 was used to inoculate osteocyte-like cultures at an MOI of 10 for 2 h, followed by removal of extracellular bacteria by lysostaphin digestion. A Nikon TiE microscope with live-cell culturing components was utilized for imaging the interaction between host cells and bacteria over a 24-h time course. Osteocyte-like cells were visualized using the differential interference contrast (DIC) channel, and *S. aureus* cells were visualized using the GFP channel (excitation at 475 nm, emission collection between 520 and 560 nm). Images of identical regions within control and infected groups were taken every 5 min, and all serial images were stitched to generate video files for each treatment group. The video files in Movie S1 and S2 demonstrated the cell activities from 4 to 24 h. The movements of one infected cell from 13 to 18 h are depicted in Fig. 1B. Osteocyte-like cell plasma membrane movement was quantified from serial static images with a 30-min interval, using ImageJ software.

TEM visualization of intracellular *S. aureus*. Osteocyte-like cultures were infected with *S. aureus* WCH-SK2 in T75 flasks. Cells were harvested in pellet form 24 h postinfection and sequentially stabilized in fixative comprising 4%, wt/vol, paraformaldehyde–1.25%, wt/vol, glycolaldehyde in PBS (pH 7.2) and then in 2%, wt/vol, osmium tetroxide in water. Cell pellets were embedded in resin blocks, and 5- μm sections were taken for transmission electron microscopy (TEM; Philips CM200) imaging.

Preparation of total RNA and reverse transcription (RT)-PCR analysis. Total RNA samples were prepared from *ex vivo* bone tissue, *in vitro* osteocyte-like cultures, and bacterial colonies by using TRIzol reagent (Life Technologies, Inc.) as per the manufacturer's instructions. For RNA isolation from bacteria, 30 min of lysostaphin (20 $\mu\text{g/ml}$)

digestion at 37°C was performed prior to the addition of TRIzol (28). cDNA was synthesized using the iScript kit (Bio-Rad Laboratories, Hercules, USA). The mRNA expression of genes of interest was measured by real-time PCR using the RT² SYBR Green quantitative PCR (qPCR) master mix (Qiagen, Limburg, the Netherlands), and relative expression was analyzed using the ΔC_T method (where C_T is threshold cycle). The efficiency of all primer pairs used (Table S1) was close to optimal, since a 10-fold dilution of the template resulted in an increase in C_T by 3.3-fold (data not shown).

Gene microarray and bioinformatics analysis. For each sample, 400 ng total RNA was amplified using the Ambion whole-transcript (WT) expression kit (ThermoFisher), and the Affymetrix GeneChip WT terminus-labeling kit (ThermoFisher) was employed to produce biotin-labeled fragmented cDNA. Each labeled cDNA sample was hybridized to the Affymetrix human gene 2.0 ST array for 17 h at 45°C. Experimental triplicates of gene chip hybridization were carried out for both the control and infected groups. Microarray chips were washed and stained with a fluorescence-labeled antibody using a model 450 Affymetrix fluidics station. Gene chips were scanned using an Affymetrix 3000 7G scanner. Microarray analysis was performed using Partek Genomics Suite v6.5. The generated raw data as .Cel files were processed using the multiarray average (RMA) method (29). Comparisons between treatments were performed by analysis of variance (ANOVA), with Benjamini-Hochberg false-discovery rate (FDR) correction for multiple tests (30). Genes were considered significantly differentially expressed (DE) using an FDR-adjusted P value of <0.01 and an estimated \log_2 fold change (\log_2FC) beyond ± 1 , giving 1,526 unique Entrez Gene identifiers considered to be DE. The set of DE identifiers was tested for enrichment of Gene Ontology (GO) terms using the Fisher exact test and a set of background genes, defined as those included on the array but with an unadjusted P value of >0.05 . GO terms with fewer than 4 steps back to the ontology roots were discarded, leaving 8,607 GO terms tested for enrichment. GO terms were considered enriched in the set of DE genes if they received a Bonferroni-adjusted P value of <0.05 , yielding 202 enriched GO terms. For the purposes of visualization, GO terms were formed into communities using the common genes within each term (31), with the “hub” or most-connected GO terms labeled in Fig. S1B.

Immunohistochemistry analyses on human bone biopsy specimens. Bone specimens for immunohistochemistry analysis were stabilized and decalcified in TheraLin tissue fixative (Grace Bio-Labs, Bend, OR, USA) at room temperature for 3 days. Samples were then embedded in paraffin, and 10- μ m sections from each of the samples were taken to perform immunohistochemistry staining. Antibody targeting *S. aureus* (AB37644; Abcam, Inc., Cambridge, MA, USA) was used at a 1:100 dilution for staining at 4°C for 1 h to detect the pathogen. Primary antibody signals were tagged by Alexa Fluor 647-conjugated rabbit anti-mouse IgG (H+L) secondary antibody (A-21239; Life Technologies, Inc.) for visualization. The specificity of antibody staining was validated by following the same staining procedures, using matched-isotype control antibody (14-4742-81; ThermoFisher) for primary detection. DAPI was employed to label nuclei of cells through all sections. All samples were imaged with an Olympus FV3000 confocal microscope. The underlying bone structure was visualized using the transmission detection function, which generates a gray-scale image of the tissue section surface.

Statistical analyses. One-tailed t tests with Welch’s correction were used for examining the differences in cell movements in Fig. 1B, mRNA levels of the chemokine gene panel in Fig. 1J, and gene expression in bone biopsy specimens between infection and iliac wing sites from the PJI cohort in Fig. 2H. One-tailed tests were used in the case of membrane movement because cells clearly changed from an inactive to an active state and in the case of host cell gene expression responses, because gene microarray analysis indicated that the genes examined were strongly induced. Two-tailed t tests with Welch’s correction were employed for examining the differences in total cell numbers in Fig. 1A and *sigB* mRNA levels in Fig. 1I, because no assumption was made for the behavior of either host cells or bacteria. One-way ANOVA tests were used for

determining the effects of various MOIs on chemokine production levels in Fig. 1K. Exact *P* values for each test are shown on the respective figure, where applicable. Statistical analysis was not applicable for data sets containing nondetectable (ND) values.

Accession number(s). Microarray experiment raw files have been deposited in the server of ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6700/>) and made available to the public.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.00415-18>.

FIG S1, PDF file, 0.3 MB.

FIG S2, PDF file, 1.8 MB.

FIG S3, PDF file, 1.7 MB.

TABLE S1, PDF file, 0.04 MB.

MOVIE S1, AVI file, 16.8 MB.

MOVIE S2, AVI file, 16.8 MB.

MOVIE S3, AVI file, 2.4 MB.

ACKNOWLEDGMENTS

We sincerely appreciate the willingness of all patients to participate in this study and the kind assistance of clinical staff from the Royal Adelaide Hospital with collection of the bone specimens. We thank Agatha Labrinidis from Adelaide Microscopy, the University of Adelaide, for assistance with microscopy imaging.

This study was funded in part by a project grant from the National Health and Medical Research Council of Australia (NHMRC; grant 1106029) and by a grant-in-aid from the Royal Adelaide Hospital Research Fund. G.J.A. was supported by an NHMRC Senior Research Fellowship.

D.Y., A.R.W., and G.J.A. framed this study and designed experiments in detail. D.Y. and A.R.W. conducted the experiments and collected data. D.Y., A.R.W., and G.J.A. analyzed and interpreted data. L.B.S. directed the collection of clinical bone specimens and provided clinical insight into the study. S.M.P. performed bioinformatics analysis. S.P.K. provided guidance for the microbiological aspects of the study. D.M.F. provided scientific insight.

REFERENCES

- Dale H, Hallan G, Espehaug B, Havelin LI, Engesaeter LB. 2009. Increasing risk of revision due to deep infection after hip arthroplasty. *Acta Orthop* 80:639–645. <https://doi.org/10.3109/17453670903506658>.
- Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. 2010. Prosthetic joint infection risk after TKA in the Medicare population. *Clin Orthop Relat Res* 468:52–56. <https://doi.org/10.1007/s11999-009-1013-5>.
- Shahi A, Tan TL, Chen AF, Maltenfort MG, Parvizi J. 2017. In-hospital mortality in patients with periprosthetic joint infection. *J Arthroplasty* 32:948–952.e1. <https://doi.org/10.1016/j.arth.2016.09.027>.
- Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. 2013. Periprosthetic joint infection increases the risk of one-year mortality. *J Bone Joint Surg Am* 95:2177–2184. <https://doi.org/10.2106/JBJS.L.00789>.
- Wimmer MD, Friedrich MJ, Randau TM, Ploeger MM, Schmolders J, Strauss AA, Hischebeth GT, Pennekamp PH, Vavken P, Gravius S. 2016. Polymicrobial infections reduce the cure rate in prosthetic joint infections: outcome analysis with two-stage exchange and follow-up \geq two years. *Int Orthop* 40:1367–1373. <https://doi.org/10.1007/s00264-015-2871-y>.
- Henderson RA, Austin MS. 2017. Management of periprosthetic joint infection: the more we learn, the less we know. *J Arthroplasty* 32: 2056–2059. <https://doi.org/10.1016/j.arth.2017.02.023>.
- Tuchscherl L, Medina E, Hussain M, Völker W, Heitmann V, Niemann S, Holzinger D, Roth J, Proctor RA, Becker K, Peters G, Löffler B. 2011. *Staphylococcus aureus* phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. *EMBO Mol Med* 3:129–141. <https://doi.org/10.1002/emmm.201000115>.
- Trouillet-Assant S, Gallet M, Nauroy P, Rasigade JP, Flammier S, Parroche P, Marvel J, Ferry T, Vandenesch F, Jurdic P, Laurent F. 2015. Dual impact of live *Staphylococcus aureus* on the osteoclast lineage, leading to increased bone resorption. *J Infect Dis* 211:571–581. <https://doi.org/10.1093/infdis/jiu386>.
- Prideaux M, Findlay DM, Atkins GJ. 2016. Osteocytes: the master cells in bone remodelling. *Curr Opin Pharmacol* 28:24–30. <https://doi.org/10.1016/j.coph.2016.02.003>.
- Bonewald LF. 2011. The amazing osteocyte. *J Bone Miner Res* 26: 229–238. <https://doi.org/10.1002/jbmr.320>.
- Bosse MJ, Gruber HE, Ramp WK. 2005. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. *J Bone Joint Surg Am* 87:1343–1347.
- Reilly SS, Hudson MC, Kellam JF, Ramp WK. 2000. In vivo internalization of *Staphylococcus aureus* by embryonic chick osteoblasts. *Bone* 26: 63–70. [https://doi.org/10.1016/S8756-3282\(99\)00239-2](https://doi.org/10.1016/S8756-3282(99)00239-2).
- de Mesy Bentley KL, Trombetta R, Nishitani K, Bello-Irizarry SN, Ninomiya M, Zhang L, Chung HL, McGrath JL, Daiss JL, Awad HA, Kates SL, Schwarz EM. 2017. Evidence of *Staphylococcus aureus* deformation, proliferation, and migration in canaliculi of live cortical bone in murine models of osteomyelitis. *J Bone Miner Res* 32:985–990. <https://doi.org/10.1002/jbmr.3055>.
- Guo G, Wang J, You Y, Tan J, Shen H. 2017. Distribution characteristics of

- Staphylococcus spp. in different phases of periprosthetic joint infection: a review. *Exp Ther Med* 13:2599–2608. <https://doi.org/10.3892/etm.2017.4300>.
15. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 28:603–661. <https://doi.org/10.1128/CMR.00134-14>.
 16. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat Rev Microbiol* 4:295–305. <https://doi.org/10.1038/nrmicro1384>.
 17. Bui LM, Hoffmann P, Turnidge JD, Zilm PS, Kidd SP. 2015. Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type. *Infect Immun* 83:470–481. <https://doi.org/10.1128/IAI.02702-14>.
 18. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM. 2011. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. *J Bone Miner Res* 26:1425–1436. <https://doi.org/10.1002/jbmr.345>.
 19. Kogawa M, Wijenayaka AR, Ormsby RT, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ. 2013. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. *J Bone Miner Res* 28:2436–2448. <https://doi.org/10.1002/jbmr.2003>.
 20. Qazi SN, Harrison SE, Self T, Williams P, Hill PJ. 2004. Real-time monitoring of intracellular Staphylococcus aureus replication. *J Bacteriol* 186:1065–1077. <https://doi.org/10.1128/JB.186.4.1065-1077.2004>.
 21. Tuchscher L, Bischoff M, Lattar SM, Noto Llana M, Pfortner H, Niemann S, Geraci J, Van de Vyver H, Fraunholz MJ, Cheung AL, Herrmann M, Völker U, Sordelli DO, Peters G, Löffler B. 2015. Sigma factor SigB is crucial to mediate Staphylococcus aureus adaptation during chronic infections. *PLoS Pathog* 11:e1004870. <https://doi.org/10.1371/journal.ppat.1004870>.
 22. Tuchscher L, Geraci J, Löffler B. 2017. Staphylococcus aureus regulator sigma B is important to develop chronic infections in hematogenous murine osteomyelitis model. *Pathogens* 6. <https://doi.org/10.3390/pathogens6030031>.
 23. Gasper NA, Petty CC, Schrum LW, Marriott I, Bost KL. 2002. Bacterium-induced CXCL10 secretion by osteoblasts can be mediated in part through Toll-like receptor 4. *Infect Immun* 70:4075–4082. <https://doi.org/10.1128/IAI.70.8.4075-4082.2002>.
 24. Tang YQ, Yeaman MR, Selsted ME. 2002. Antimicrobial peptides from human platelets. *Infect Immun* 70:6524–6533. <https://doi.org/10.1128/IAI.70.12.6524-6533.2002>.
 25. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. 2001. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. *J Immunol* 167:623–627.
 26. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. 2006. Staphylococcus aureus small colony variants in prosthetic joint infection. *Clin Infect Dis* 43:961–967. <https://doi.org/10.1086/507633>.
 27. Ou JJ, Drilling AJ, Cooksley C, Bassiouni A, Kidd SP, Psaltis AJ, Wormald PJ, Vreugde S. 2016. Reduced innate immune response to a Staphylococcus aureus small colony variant compared to its wild-type parent strain. *Front Cell Infect Microbiol* 6:187. <https://doi.org/10.3389/fcimb.2016.00187>.
 28. Atshan SS, Shamsudin MN, Lung LT, Ling KH, Sekawi Z, Pei CP, Ghaznavi-Rad E. 2012. Improved method for the isolation of RNA from bacteria refractory to disruption, including *S. aureus* producing biofilm. *Gene* 494:219–224. <https://doi.org/10.1016/j.gene.2011.12.010>.
 29. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 4:249–264. <https://doi.org/10.1093/biostatistics/4.2.249>.
 30. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B Stat Methodol* 57:289–300.
 31. Mäkinen VP, Forsblom C, Thorn LM, Wadén J, Kaski K, Ala-Korpela M, Groop PH. 2009. Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study). *Cardiovasc Diabetol* 8:54. <https://doi.org/10.1186/1475-2840-8-54>.